Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OCUP |
---|---|---|
09:32 ET | 3566 | 1.3 |
09:36 ET | 225 | 1.3 |
09:38 ET | 400 | 1.2924 |
09:39 ET | 1000 | 1.29 |
09:41 ET | 145 | 1.2823 |
09:43 ET | 1000 | 1.2895 |
09:48 ET | 100 | 1.28 |
09:52 ET | 500 | 1.2988 |
09:54 ET | 1000 | 1.2964 |
09:56 ET | 1100 | 1.295 |
09:57 ET | 1000 | 1.2994 |
10:01 ET | 400 | 1.2904 |
10:08 ET | 1525 | 1.29 |
10:15 ET | 2891 | 1.2959 |
10:30 ET | 1086 | 1.29 |
10:39 ET | 300 | 1.2901 |
10:42 ET | 2948 | 1.295 |
10:50 ET | 3949 | 1.3 |
10:51 ET | 200 | 1.2994 |
11:06 ET | 25159 | 1.29 |
11:09 ET | 14051 | 1.28 |
11:11 ET | 100 | 1.2788 |
11:13 ET | 13094 | 1.2599 |
11:18 ET | 100 | 1.2699 |
11:20 ET | 1000 | 1.2699 |
11:40 ET | 300 | 1.28 |
11:45 ET | 100 | 1.28 |
11:47 ET | 200 | 1.2791 |
11:56 ET | 3899 | 1.2502 |
11:58 ET | 2598 | 1.26 |
12:07 ET | 2768 | 1.27 |
12:16 ET | 100 | 1.28 |
12:18 ET | 200 | 1.2822 |
12:27 ET | 193 | 1.28 |
12:30 ET | 1200 | 1.281934 |
12:39 ET | 999 | 1.2847 |
12:52 ET | 400 | 1.29 |
01:01 ET | 482 | 1.281 |
01:12 ET | 1300 | 1.29 |
01:24 ET | 2000 | 1.2885 |
01:26 ET | 100 | 1.285 |
01:28 ET | 773 | 1.29 |
01:30 ET | 439 | 1.29 |
01:33 ET | 100 | 1.29 |
01:53 ET | 100 | 1.285 |
01:57 ET | 480 | 1.28 |
02:15 ET | 1000 | 1.285 |
02:24 ET | 2000 | 1.285 |
02:29 ET | 100 | 1.28 |
02:44 ET | 400 | 1.29 |
03:03 ET | 500 | 1.285 |
03:23 ET | 100 | 1.28 |
03:38 ET | 6697 | 1.2842 |
03:41 ET | 100 | 1.29 |
03:43 ET | 230 | 1.285 |
03:45 ET | 795 | 1.285 |
03:52 ET | 1000 | 1.285 |
03:54 ET | 6103 | 1.285 |
03:59 ET | 1898 | 1.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ocuphire Pharma Inc | 34.1M | -2.3x | --- |
Evofem Biosciences Inc | 913.0K | 0.0x | --- |
CV Sciences Inc | 8.4M | -3.0x | -25.43% |
Cyanotech Corp | 4.8M | -0.9x | --- |
Earth Science Tech Inc | 49.5M | 28.2x | --- |
Sunshine Biopharma Inc | 3.1M | 0.0x | --- |
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.1M |
---|---|
Revenue (TTM) | $16.4M |
Shares Outstanding | 26.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-0.55 |
Book Value | $2.08 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.